A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4.

Background: Easy-to-use insulin devices are an important tool in the treatment of diabetes. In this study, injection force requirements and dosage scale displays were evaluated for NovoPen 3 and NovoPen 4 (both from Novo Nordisk A/S, Copenhagen, Denmark).

Methods: To simulate 5 years of expected lifetime usage, 5,475 injections were performed automatically.